Sensorion (ALSEN.PA) Akcija Kursas
Sensorion Kursas
Per pastaruosius 13 metus Sensorion pajamos augo 164,9 % kasmet ir pasiekė 6,65 mln. EUR. Sensorion grynoji marža −390,4 % yra sumažėjo palyginti su −381,7 % prieš kelerius metus. Sensorion 12 mėn. konsensuso tikslinė kaina yra 2,30 EUR, apie žemiau kursą 73,4 %. Iš 13 analitikų 12 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Sensorion akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Sensorion akcija ir akcijų analizė
Dažnai užduodami klausimai apie Sensorion akciją
Sensorion SA is a biopharmaceutical company specializing in the development of innovative therapies to address inner ear disorders. The company's business model revolves around the research, development, and commercialization of novel treatments for conditions such as vertigo and hearing loss. Sensorion SA aims to leverage its expertise in inner ear biology and drug development to create innovative therapies that can provide significant benefits to patients. With a focus on advancing its proprietary pipeline of drug candidates, Sensorion SA is dedicated to meeting the unmet medical needs in the field of inner ear disorders.
Sensorion SA is primarily active in the biotechnology industry.
The main competitors of Sensorion SA in the market are [competitor #1], [competitor #2], and [competitor #3]. These companies operate in the same industry as Sensorion SA and provide similar products or services. Despite facing competition, Sensorion SA has positioned itself as a key player in the market with its unique offerings. By continually innovating and delivering high-quality solutions, Sensorion SA maintains a competitive edge in the industry.
Sensorion SA is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for inner ear disorders. Founded in 2009, Sensorion has a strong focus on addressing unmet medical needs in the field of hearing loss and vestibular disorders. The company's research and development efforts primarily revolve around the identification, selection, and development of small molecules designed to protect, regenerate, and restore inner ear cells. With a deep commitment to improving the quality of life for patients suffering from hearing and balance disorders, Sensorion SA continues to pursue groundbreaking solutions to these debilitating conditions.
Sensorion SA, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed Phase 1 clinical trials for its novel therapy targeting inner ear disorders. It also received Orphan Drug Designation from the FDA for its product candidate, confirming its potential to address unmet medical needs. Furthermore, Sensorion SA successfully initiated Phase 2 clinical trials, demonstrating promising results in patients with sudden sensorineural hearing loss. The company's collaborations with renowned academic institutions highlight its commitment to advancing research in the field. Overall, Sensorion SA's achievements reflect its dedication to revolutionizing treatments for inner ear disorders, positioning it as a key player in the industry.
Sensorion SA is primarily present in several countries and regions globally. These include the United States, Europe, and Asia. The company has established a strong presence in the United States, where it conducts significant research and development activities. In Europe, Sensorion SA has partnerships and collaborations with various academic institutions and pharmaceutical companies. Additionally, the company has expanded its reach in Asia through strategic alliances and distribution agreements. With its global presence, Sensorion SA aims to address the unmet medical needs of patients suffering from inner ear disorders and provide innovative solutions in the field of hearing and balance disorders.
Sensorion SA is a leading biopharmaceutical company dedicated to developing innovative therapies for inner ear disorders. The company's values revolve around scientific excellence, patient-centered approach, and commitment to improving the lives of individuals suffering from vestibular and hearing impairments. Sensorion SA aims to provide effective and safe treatment solutions while prioritizing the needs and well-being of patients. With a strong corporate philosophy grounded in research and development, Sensorion SA strives to address the unmet medical needs in the field of auditory disorders, aiming to make a meaningful impact on the lives of individuals affected by these conditions.
Analitikai šiuo metu nustato vidutinę Sensorion akcijos tikslinę kainą 2,42 EUR (mediana: 2,30 EUR), t. y. −72,0 % palyginti su paskutine kaina. Konsensusas pagrįstas 13 analitikų reitingais.
14 analitikai šiuo metu vertina Sensorion akciją: 13 rekomenduoja pirkti, 1 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad Sensorion gaus 4,55 mln. EUR pajamų ir −169,83 EUR pelno akcijai.
Sensorion akcija (ALSEN.PA) kotiruojama 5 biržose, įskaitant: Frankfurt (RFM.F), München (RFM.MU), Düsseldorf (RFM.DU), Paris (ALSEN.PA).
Sensorion SA is a French biotechnology company specializing in the development of novel therapies for the treatment of inner ear disorders and hearing loss. The company focuses on researching and developing drugs tailored to the specific needs of patients. Sensorion aims to create innovative products and therapies in the field of otolaryngology to meet the needs of patients.
tikėtina pelnas Sensorion yra 4,55 mln. EUR. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Sensorion yra −1,02 mlrd. EUR. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Sensorion šiuo metu yra −0,05. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Sensorion akcijos vertę.
Kainų ir pardavimų santykis (KUV) Sensorion šiuo metu yra 11,42. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Sensorion akcijos įvertinimo metrika.
Eulerpool kokybės balas Sensorion yra 4/10.
Sensorion ISIN yra FR0012596468. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Sensorion WKN yra A14SVV. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Sensorion prekybos žymė yra ALSEN.PA. Ši biržos žymė naudojama Sensorion akcijoms prekiauti biržoje.
Sensorion akcija
Sensorion Pagrindiniai konkurentai
Sensorion Biržos simbolis
Sensorion FIGI
Visos Sensorion pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Sensorion akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Sensorion. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: